Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 11/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18406249 | 0.92 | L3MBTL1 (0.71) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL927230 | 0.84 | PKM (0.62) | L3MBTL1ALDH1A1 | |
| SCHEMBL927098 | 0.83 | MAPT (0.72) | L3MBTL1GAAMAPTLMNAACACB | |
| SCHEMBL834525 | 0.83 | L3MBTL1 (0.88) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL12422212 | 0.83 | L3MBTL1 (0.44) | L3MBTL1GAAMAPTMAOBACACB | |
| SCHEMBL2714295 | 0.82 | MAOB (0.62) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL18868405 | 0.81 | L3MBTL1 (1.00) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL3046764 | 0.80 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL2985635 | 0.80 | GSK3B (0.53) | L3MBTL1GAAMAPTACACB | |
| SCHEMBL7737450 | 0.80 | L3MBTL1 (0.64) | L3MBTL1GAAMAPTALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| EP-1463735-B1 | IMIDAZO¬2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS INC (CA) | 2009-08-12 | — | — | EP | disclosed |
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | AEGERA THERAPEUTICS, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-11-15 | — | — | US | disclosed |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | disclosed |
| EP-1463735-A1 | IMIDAZO[2,1-B]-1,3,4-THIADIAZOLE SULFONAMIDES | Aegera Therapeutics Inc. (CA) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003051890-A1 | IMIDAZO [2,1-B]-1,3,4-THIADIAZOLE SUFLONAMIDES | AEGERA THERAPEUTICS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | L3MBTL1 3085/4885GAA 3787/4885MAPT 1345/4885 |
| US-20090042953-A1 | IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES | PMP22, SMN1; SMN2, BDNF | L3MBTL1 2821/4885GAA 4035/4885MAPT 1078/4885 |
| US-20070265319-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | L3MBTL1 3085/4885GAA 3787/4885MAPT 1345/4885 |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | L3MBTL1 3085/4885GAA 3787/4885MAPT 1345/4885 |
| US-20070238768-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | L3MBTL1 3085/4885GAA 3787/4885MAPT 1345/4885 |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | L3MBTL1 3085/4885GAA 3787/4885MAPT 1345/4885 |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | L3MBTL1 3085/4885GAA 3787/4885MAPT 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.